144256-12-2

Basic information

• Product Name: 2,2-dimethyl-1,3-dioxolan-4S-ylmethyl 3-<4-<2(S),3-epoxypropoxy>phenyl>propionate
• Synonyms: 2,2-dimethyl-1,3-dioxolan-4S-ylmethyl 3-<4-<2(S),3-epoxypropoxy>phenyl>propionate
• CAS NO: 144256-12-2
• Molecular Weight: 336.385
• Mol File: 144256-12-2.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2,2-dimethyl-1,3-dioxolan-4S-ylmethyl 3-<4-<2(S),3-epoxypropoxy>phenyl>propionate(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2-dimethyl-1,3-dioxolan-4S-ylmethyl 3-<4-<2(S),3-epoxypropoxy>phenyl>propionate(144256-12-2)
• EPA Substance Registry System: 2,2-dimethyl-1,3-dioxolan-4S-ylmethyl 3-<4-<2(S),3-epoxypropoxy>phenyl>propionate(144256-12-2)

Safety Data

• Hazardous Substances Data: 144256-12-2(Hazardous Substances Data)

Upstream product

• 23788-74-1 (R)-2,2-dimethyl-1,3-dioxolane-4-ylmethyl p-toluenesulfonate 
• 23735-43-5 (S)-1-O-tosyl-2,3-O-isopropylideneglycerol 
• 70987-78-9 (S)-Glycidyl tosylate 
• 133242-63-4 2,2-dimethyl-1,3-dioxolan-4R-ylmethyl 3-(4-hydroxyphenyl)propionate 
• 144256-11-1 3-(4-hydroxyphenyl)propionic acid [(4S)-2,2-dimethyl-1,3-dioxolan-4-yl]methyl ester 
• 501-97-3 4-hydroxyphenylpropionic acid 
• 115314-14-2 (2s)-(+)-glycidyl 3-nitrobenzenesulfonate 

Downstream Products

• 144481-98-1 Landiolol hydrochloride 
• 133242-30-5 2,2-dimethyl-1,3-dioxolan-4S-ylmethyl 3-<4-<3-<2-(morpholinocarbonylamino)ethylamino>-2S-hydroxypropoxy>phenyl>propionate 
• 133242-29-2 3-[4-((S)-2-Hydroxy-3-{2-[(morpholine-4-carbonyl)-amino]-ethylamino}-propoxy)-phenyl]-propionic acid (R)-2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester 

Relevant articles and documents

Preparation method of landiolol hydrochloride

The invention relates to a preparation method of landiolol hydrochloride, in particular to the selection of a reaction solvent 1,4-dioxane. The landiolol hydrochloride prepared by means of the methodcan prevent the generation of ester exchange impurities, the operation is simple, the reaction yield is high, the method is suitable for industrial large-scale production, and a crude drug and the preparation of the crude drug have better safety performance, effectiveness and stability, and have significant use in preparing drugs used for urgently treating arrhythmia and postoperative dynamic monitoring abnormality.

Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101

A novel, highly cardioselective ultra short-acting β-blocker, ONO-1101, has been developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. This agent is approximately nine times more potent in β-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. This β-blocking drug has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease and represents a major therapeutic advance in the treatment of heart disease.